In the following tables, sales are disaggregated by category, sales by geographic market and sales by product data. The following breaks down sales into the following categories (in thousands):


	Three Months Ended
	March 31, 2023		April 1, 2022
Non-consignment sales	$	67,163	$	57,569
Consignment sales		6,365		5,631
Total net sales	$	73,528	$	63,200

The Company markets and sells its products in over 75 countries and conducts its manufacturing in the United States. Other than China and Japan, the Company does not conduct business in any country in which its sales exceed 10% of worldwide consolidated net sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):


	Three Months Ended
	March 31, 2023		April 1, 2022
Domestic	$	4,551	$	2,630
Foreign:
China		35,090		28,239
Japan		10,936		11,633
Other(1)		22,951		20,698
Total foreign sales		68,977		60,570
Total net sales	$	73,528	$	63,200

(1)

No other location individually exceeds 10% of the total sales.

100% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line was as follows (in thousands):


	Three Months Ended
	March 31, 2023		April 1, 2022
ICLs	$	70,625	$	58,675
Other product sales:
Cataract IOLs		1,476		2,902
Other surgical products(1)		1,427		1,623
Total other product sales		2,903		4,525
Total net sales	$	73,528	$	63,200

(1) Other surgical products include delivery systems and normal recurring sales adjustments such as sales return allowances.

One customer, the Company’s distributor in China, accounted for 48% and 45% of net sales for the three months ended March 31, 2023 and April 1, 2022, respectively. As of March 31, 2023 and December 30, 2022, respectively, one customer, the Company’s distributor in China, accounted for 55% and 59% of consolidated trade receivables.